Navigation Links
Abbott Opens New Pharmaceutical Research Laboratory in Singapore

SINGAPORE, Jan. 20 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced the opening of a new pharmaceutical analytical research laboratory in Singapore's Biopolis research park. This new facility, Abbott's first pharmaceutical research and development site in Southeast Asia, will conduct stability studies, including studies on active pharmaceutical ingredients and novel formulations, to support global regulatory requirements for new pharmaceutical products. The work done at the laboratory will enable Abbott to accelerate the development of innovative investigational medicines and potentially deliver new treatments to patients faster in areas such as neuroscience and cancer. The opening was announced at a dedication and ribbon-cutting ceremony earlier today.

"Abbott has continually increased its investment in R&D over the last decade, resulting in a promising pipeline," said John M. Leonard, M.D., senior vice president, Pharmaceuticals, Research and Development, Abbott. "To realize the potential from the growth in Abbott's early stage pipeline requires the resources of a truly global R&D organization and the scientific talent available in Singapore made it a logical choice for Abbott's expansion in the region."

"We warmly welcome Abbott's expansion into pharmaceutical R&D from its established base in Singapore, which includes nutritional manufacturing and regional headquarters. This project fits well with our intent for Singapore to be an international biomedical sciences research cluster advancing human health. From its new laboratory at the Biopolis, Abbott will be able to access the extensive network of public and private sector researchers, academics and clinicians nearby," said Yeoh Keat Chuan, executive director, Biomedical Sciences, Singapore Economic Development Board.

Long known in Singapore for its nutritional products, Abbott is also building a nutrition manufacturing plant in Singapore, its largest nutritional investment ever. In addition, Abbott has expanded its presence in the country over the last few years with the launch of several key products, including HUMIRA(R) and the XIENCE V(TM) drug-eluting stent. Singapore is also home to regional headquarters offices for several Abbott businesses including nutrition, pharmaceuticals and diagnostics.

The Singapore laboratory is Abbott's latest global investment in facilities and resources to advance its pipeline. These initiatives include the Formulation Development Center that opened in Abbott Park, Ill., USA, in June 2008 and expansions at Abbott's drug delivery operations, SOLIQS, announced in Ludwigshafen, Germany in October 2008.

Scientific Innovation at Abbott

Abbott was founded on the idea that using new technologies and treatment approaches could dramatically improve the quality of care for patients. Today, Abbott's 7,000 scientists around the world are focused on using breakthrough science to develop effective treatments and solve unmet medical needs. Abbott's global pharmaceutical research and development organization is focused on the discovery and development of novel molecular targets and new drug candidates in the areas of immunology, oncology, virology, central nervous system/pain and dyslipidemia.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site athttp:///

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott to Present at Bear Stearns Healthcare Conference
2. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
3. Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance
4. Abbott Declares 335th Consecutive Quarterly Dividend
5. Abbott Again Honored as Top Company for Working Moms
6. Abbotts HUMIRA(R) (adalimumab) Honored With Prestigious Galen Prize for Innovation in Patient Care
7. Abbott Hosts Conference Call for Third-Quarter Earnings
8. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
9. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
10. Abbott Again Honored as a Leader in Diversity
11. Abbott Researchers Target Neuronal Nicotinic Receptors for Treatment of Pain and Cognition
Post Your Comments:
(Date:10/12/2015)... ... October 12, 2015 , ... ... on being awarded a contract with the U.S. Biomedical Advanced Research and Development ... development and procurement of its ReCell® Autologous Cell Harvesting Device under a U.S. ...
(Date:10/12/2015)... ... October 12, 2015 , ... The translation for ARIS® 7.x ... migration of complete ARIS installations into the Microsoft world. The ARIS models will be ... Visio® is very familiar for both IT and Office users it is acknowledged as ...
(Date:10/12/2015)... ... October 12, 2015 , ... The ... to 8:00 pm at the Sheraton Philadelphia Hotel, 3549 Chestnut Street, Philadelphia, PA ... attending from across the country. All specialties will be represented. Attendees will enjoy ...
(Date:10/12/2015)... Greifensee, Switzerland (PRWEB) , ... October 12, 2015 ... ... of new product upgrades designed to streamline laboratory processes. In addition, METTLER TOLEDO ... a free Lean Lab Checklist to help improve productivity through the ...
(Date:10/12/2015)... ... ... On Sept. 26, the team at Dynamic Fitness joined supporters from 58 ... Houston Zoo during September's Childhood Cancer Awareness Month. The Walk/Run helped to raise funds ... up with the idea to involve his team with the walk in an effort ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... 12, 2015 Device usage in healthcare continues ... integrate these devices into existing clinical workflow. In response, ... and mobility solutions, has launched the SV10 series of ... a wide array of laptops and tablets. In addition, ... exclusively for Microsoft Surface and is compatible with all ...
(Date:10/12/2015)... October 12, 2015 ... to grow at 7.2% CAGR, microscopy market ... rising focus on nanotechnology, technological advancements, and ... report available with ... . --> Complete report on ...
(Date:10/12/2015)... Oct. 12, 2015 Indivior PLC (LON: INDV) today ... Delaware granted the Company,s motion to ... New Drug Application (ANDA) No. 205299 to market a generic ... naloxone) Sublingual Film (CIII) in the United States ... Since August 2013, Indivior has received Paragraph IV certifications from ...
Breaking Medicine Technology: